ATMPS Ltd has created the Hataali platform which digitises the end to end, cell and gene therapy process, providing immutable digital records with full chain of custody, identity and condition data. It can be used for clinical trials and commercially available therapies.
Hataali allows clinics, pharmaceutical companies, and couriers to communicate and coordinate their activities in real time. Hataali is modular and interoperable, integrating existing systems. It is patented and future-proof utilising blockchain technology.
Hospitals can digitally enrol and screen patients and order multiple treatments from multiple pharmaceutical companies through a single portal.
Pharmaceutical companies can easily administer, monitor and schedule treatments to multiple clinics in multiple countries, over one platform. Our digital analytics dashboards provide data driven decision making capabilities.
The Hataali platform significantly reduces implementation times and costs to users of the cell and gene therapy ecosystem. It increases efficiency, ensures patient safety and provides regulatory compliance.